PDS Biotechnology (NASDAQ: PDSB)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.220 | -0.320 | -0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of PDS Biotechnology (NASDAQ: PDSB) through any online brokerage.
Other companies in PDS Biotechnology’s space includes: AVEO Pharmaceuticals (NASDAQ:AVEO), OncoCyte (NASDAQ:OCX), Immuneering (NASDAQ:IMRX), Atossa Therapeutics (NASDAQ:ATOS) and Humanigen (NASDAQ:HGEN).
The latest price target for PDS Biotechnology (NASDAQ: PDSB) was reported by HC Wainwright & Co. on Thursday, August 12, 2021. The analyst firm set a price target for 15.00 expecting PDSB to rise to within 12 months (a possible 192.40% upside). 5 analyst firms have reported ratings in the last year.
The stock price for PDS Biotechnology (NASDAQ: PDSB) is $5.13 last updated Today at May 16, 2022, 7:15 PM UTC.
There are no upcoming dividends for PDS Biotechnology.
PDS Biotechnology’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for PDS Biotechnology.
PDS Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.